loading

About Author

At BILM, we believe in the power of Educating, Accrediting and inspiring Excellence in Longevity Medicine for doctors in the UK.

Contact Info

0

Your Cart 0

No products in the basket.

1. Scope

What this covers: Assessment and modulation of chronic low-grade, sterile inflammation (“inflammaging”) as a modifiable driver of age-related disease in ostensibly healthy or at-risk adults attending a private UK longevity clinic. It covers measurement (hsCRP, IL-6, emerging methylation-based scores), lifestyle and dietary interventions, and pharmacological/nutraceutical agents (omega-3, ARBs, metformin, low-dose colchicine, IL-1β/IL-6 pathway agents, senolytics, rapalogues).

What this does NOT cover: Diagnosis or management of defined autoimmune/autoinflammatory disease, active infection, or malignancy; acute inflammation; paediatric care; and licensed immunosuppression for rheumatological indications. These remain the remit of conventional primary and secondary care.

Positioning: All recommendations here are adjunctive to conventional care. Inflammaging is a research construct, not a licensed disease indication; no drug is licensed in the UK “to reduce inflammaging” or “to extend lifespan”. Every pharmacological use described for this purpose is therefore off-label unless otherwise stated.

2. Background and pathophysiology

  • Inflammaging is a chronic, low-grade, sterile pro-inflammatory state that increases with age and is mechanistically implicated in cardiovascular disease, neurodegeneration, metabolic syndrome, sarcopenia and frailty (Franceschi framework; Moskalev et al., Ageing Research Reviews, 2026; Müller & Di Benedetto, Frontiers in Immunology, 2025).
  • Key upstream mechanisms (robust in human observational/mechanistic data): accumulation of senescent cells with a senescence-associated secretory phenotype (SASP); persistent innate-immune (NF-κB, inflammasome) activation; immunosenescence and thymic involution; metabolic dysregulation and visceral adiposity; and gut dysbiosis with increased intestinal permeability (Zanders et al., Immunological Reviews, 2026; Hamczyk et al., JACC, 2020).
  • Core signalling nodes targeted by interventions: NF-κB, mTOR, AMPK, JAK/STAT, IL-1β→IL-6→CRP axis, and specialised pro-resolving mediator (SPM) pathways (Mensah et al., JACC, 2026).

Human causal anchor (highest-quality mechanistic evidence): CANTOS (canakinumab, IL-1β blockade, n>10,000) demonstrated that lowering inflammation without changing lipids reduces cardiovascular events, establishing inflammation as a causal contributor to at least one major age-related disease (Forman et al., JACC, 2023). This is the strongest human evidence that the pathway — not merely the biomarker — is modifiable to clinical benefit.

Preclinical only (mechanistic plausibility, do not extrapolate to clinical benefit): rapamycin delaying cardiac ageing in mice/dogs; metformin slowing multi-organ ageing in primates; senolytics extending murine lifespan and reducing organ dysfunction. These are hypothesis-generating and have no confirmatory longevity RCT data in humans (Zanders et al., 2026; Kritchevsky & Cummings, JAMA, 2025).

3. Evidence base and grading

Overall, the human evidence supports that inflammatory biomarkers are modifiable and that, in cardiovascular secondary prevention, inflammation reduction lowers hard events. Evidence that reducing inflammation in healthy/longevity populations extends healthspan or lifespan is absent from RCTs and rests on biomarker surrogates and observational cohorts.

GRADE-style summary by outcome:

  • Reduction in inflammatory biomarkers (hsCRP, IL-6) with nutraceutical/drug interventions — Moderate certainty. Meta-analysis of 49 RCTs found significant IL-6 reduction with probiotics (SMD −0.68), ARBs (−0.37) and omega-3 (−0.19); CRP reduction with probiotics (−0.43 mg/L), ARBs (−0.20), omega-3 (−0.17) and metformin (−0.16); resveratrol and vitamin D showed no significant effect (Custodero et al., 2018). Downgraded for inconsistency (substantial heterogeneity). Strength: Conditional recommendation to use omega-3/anti-inflammatory diet where biomarker reduction is the goal — but this is a surrogate endpoint.
  • Hard cardiovascular event reduction via inflammation lowering (secondary prevention) — Moderate-to-High certainty. CANTOS (canakinumab) and colchicine trials (COLCOT, LoDoCo2); updated meta-analysis including neutral CLEAR-SYNERGY shows ~25% RRR in MACE for colchicine (HR 0.75, 95% CI 0.56–0.93) (Mensah et al., 2026). This applies to established atherosclerosis, not primary longevity use. Strength: Strong recommendation within its licensed CV indication; not established for general longevity.
  • All-cause mortality / healthspan extension from anti-inflammatory therapy in healthy adults — Very low certainty. No RCT demonstrates this. ASPREE showed daily aspirin did not lower all-cause mortality or mobility loss in healthy older adults (Forman et al., 2023). Strength: Recommend against routine anti-inflammatory pharmacotherapy for longevity outside trials.
  • Lifestyle (exercise, Mediterranean/DASH diet, smoking cessation, weight loss) reducing inflammation — Moderate-to-High certainty; and reducing CVD events — High certainty (Mensah et al., 2026). Strength: Strong recommendation.
  • Metformin as a gerotherapeutic — Low certainty (mixed clinical trial data; TAME/VA-IMPACT pending) (Kritchevsky & Cummings, 2025; Forman et al., 2023). Strength: Only in research for the ageing indication.
  • Senolytics (dasatinib+quercetin, fisetin) and rapalogues — Very low certainty; early-phase only, well-tolerated but no efficacy on ageing endpoints (Kritchevsky & Cummings, 2025). Strength: Only in research.

4. Patient selection and indications

Who may benefit (for assessment and lifestyle intervention — the guideline-backed core):

  • Middle-aged and older adults with elevated cardiometabolic risk (visceral adiposity, metabolic syndrome, prediabetes).
  • Adults with persistently elevated hsCRP >2 mg/L in whom reversible causes have been excluded — a marker of “residual inflammatory risk” (Mensah et al., 2026).
  • Older adults with early frailty/sarcopenia where inflammaging is contributory.

Inclusion thresholds (pragmatic, expert-consensus): age ≥40; hsCRP 2–10 mg/L on repeat testing (≥2 measurements, ≥2 weeks apart, no acute illness); absence of a defined inflammatory disease.

Exclusion / high-risk groups:

  • hsCRP >10 mg/L → investigate for occult infection, autoimmune disease or malignancy before attributing to inflammaging; refer as appropriate.
  • Active or recent infection, active malignancy, defined autoimmune disease.
  • Immunosuppression, significant renal or hepatic impairment (relevant to colchicine, metformin, IL-pathway agents).
  • Pregnancy/breastfeeding.

Regulatory/ethical status:

  • On-label: low-dose colchicine 0.5 mg daily for established ASCVD/high CV risk (its own indication, not “longevity”); ARBs for hypertension; omega-3 as dietary/food supplement.
  • Off-label: metformin, colchicine, aspirin used specifically to “reduce inflammaging”.
  • Only in research / trial frameworks: senolytics, rapalogues, IL-6 ligand inhibitors (ziltivekimab/clazakizumab — phase 3 pending, results expected late 2026–2027), canakinumab for longevity.
  • All off-label/experimental use requires documented informed consent covering the absence of longevity-outcome evidence and reliance on surrogate biomarkers.

5. Assessment and baseline work-up

History and examination: cardiometabolic risk factors, smoking, alcohol, diet quality (consider Dietary Inflammatory Index framework), physical activity, sleep, medications, periodontal/chronic infective foci, family history. Examination: BP, waist circumference, BMI, frailty screen (e.g., gait speed/grip strength) in older adults.

Baseline investigations:

  • Inflammatory markers: hsCRP (repeat to confirm); IL-6 where available. Interpret hsCRP >2 mg/L as elevated residual inflammatory risk; >10 mg/L prompts a search for a specific cause.
  • Confounder screen: FBC, renal and liver function, HbA1c, lipid profile, ferritin, TSH; consider ESR.
  • Cardiometabolic: lipids including consideration of Lp(a) once; QRISK3 for CV risk stratification.
  • Emerging/optional (research-adjacent, not validated for clinical decisions): DNA-methylation “epigenetic inflammation score” (EIS) has outperformed CRP for association with chronic-inflammation-related traits (Verschoor et al., Aging Cell, 2023); DunedinPACE/GrimAge pace-of-ageing clocks correlate with inflammatory burden (Humaloja et al., Scientific Reports, 2026). Present these as experimental; do not base treatment decisions on them.

Risk stratification (benefit vs harm):

  • Low: hsCRP <2, good function → lifestyle optimisation only.
  • Moderate: hsCRP 2–10 with cardiometabolic risk → intensify lifestyle ± statin optimisation ± omega-3.
  • High: established ASCVD with residual inflammation → consider licensed low-dose colchicine (usually via/with cardiology).

Baseline documentation: two hsCRP values, IL-6 if measured, renal/hepatic function, medication list, CV risk score, functional measures, and explicit consent record for any off-label agent.

6. Dosing regimens and practical implementation

Lifestyle (robust human data — first-line):

  • Aerobic exercise: ≥150 min/week moderate or ≥75 min/week vigorous; reduces resting CRP and increases SPM production (Mensah et al., 2026).
  • Diet: Mediterranean or DASH pattern — fruits, vegetables, whole grains, legumes, nuts, olive oil; oily fish 2–3×/week (EPA+DHA); minimise red/processed meat, refined carbohydrate, sugary drinks (Mensah et al., 2026).
  • Smoking cessation and weight loss to attenuate systemic inflammation.

Nutraceuticals (moderate biomarker evidence, surrogate endpoint):

  • Omega-3 (EPA+DHA): typical 1–2 g/day of combined EPA+DHA reduces IL-6 and CRP modestly (Custodero et al., 2018). Higher prescription-strength icosapent doses fall under separate cardiovascular indications.
  • Probiotics: largest biomarker effect in meta-analysis but heterogeneous strains/doses; no standardised regimen can be recommended — present as low-certainty.
  • Resveratrol and vitamin D: no significant anti-inflammatory biomarker effect — do not recommend for this purpose (Custodero et al., 2018).

Pharmacological (off-label for longevity unless noted):

  • Low-dose colchicine 0.5 mg once daily — licensed and evidence-based for CV event reduction in established ASCVD/high-risk; not established as a general longevity agent. Adjunct to lipid-lowering; avoid at time of acute ischaemia (Mensah et al., 2026).
  • ARBs — where a hypertension indication coexists, they offer an ancillary anti-inflammatory effect; do not initiate solely for inflammaging.
  • Metformin — off-label for ageing; TAME/VA-IMPACT will inform. If used (e.g., in prediabetes), typical titration 500 mg to 1–2 g/day with food. Only in research for a pure longevity indication.
  • Senolytics (dasatinib+quercetin, fisetin), rapalogues (sirolimus/everolimus), IL-6 ligand inhibitors — do not prescribe for longevity outside a trial; dosing extrapolated from oncology/transplant/rheumatology carries disproportionate risk without efficacy evidence.

Distinguishing evidence tiers: lifestyle + omega-3 = supported by human RCT/meta-analytic biomarker data (and lifestyle by hard-outcome data); colchicine = hard-outcome data but only in CV secondary prevention; metformin/senolytics/rapalogues = extrapolation requiring caution.

7. Monitoring, safety and follow-up

Monitoring plan:

  • Clinical: symptoms, BP, weight/waist, functional measures; adverse effects of any agent.
  • Laboratory: repeat hsCRP (± IL-6) at 3 months to assess biomarker response, then 6–12 monthly. Renal and hepatic function before and during colchicine/metformin. FBC if on any agent affecting marrow/infection risk.
  • Ageing biomarkers: if epigenetic/pace-of-ageing clocks are tracked, do so as research adjuncts, annually at most, without using them to drive therapy changes.

Timepoints: baseline → 3 months (response and tolerability) → 6–12 monthly thereafter.

Adverse effects:

  • Colchicine: GI intolerance (common); pneumonia/serious infection signal in COLCOT (not confirmed in LoDoCo2/CLEAR or pooled meta-analyses); myotoxicity and marrow suppression, especially with CYP3A4/P-gp inhibitors or renal/hepatic impairment (Imbesi et al., 2025; Mensah et al., 2026).
  • IL-1β (canakinumab): small but significant increase in fatal infection/sepsis and neutropenia (Forman et al., 2023).
  • Metformin: GI effects, B12 deficiency, rare lactic acidosis in renal impairment.
  • Aspirin (if considered): no mortality/mobility benefit in healthy elderly and increased bleeding — recommend against for longevity (ASPREE).
  • IL-6 inhibitors (tocilizumab/ziltivekimab): theoretical opportunistic infection risk; ziltivekimab may have a more favourable profile (ligand binding, gp130 preservation) — phase 3 pending (Imbesi et al., 2025).

Required actions for abnormal findings: rising hsCRP >10 mg/L → investigate for infection/malignancy/autoimmune disease. New cytopenia, myopathy, or infection on colchicine → stop and reassess. Deranged renal/hepatic function → dose-reduce or stop colchicine/metformin.

Interactions: colchicine with clarithromycin, ketoconazole, fluconazole, ciclosporin, other CYP3A4/P-gp inhibitors (avoid/hold) — risk of toxic accumulation (Mensah et al., 2026). Avoid stacking multiple immunomodulators.

Special populations: avoid colchicine, metformin and experimental immunomodulators in pregnancy/breastfeeding without specialist input; dose-limit or avoid in renal/hepatic impairment; heightened caution in frailty and extremes of age (higher infection and drug-toxicity risk).

8. Contraindications and cautions

Absolute:

  • Colchicine: severe renal or hepatic impairment; concomitant P-gp/strong CYP3A4 inhibitor with renal/hepatic impairment; known hypersensitivity.
  • Any immunomodulator: active serious infection.
  • Metformin: eGFR <30 mL/min/1.73 m².

Relative / specialist advice required:

  • Established ASCVD needing colchicine → coordinate with cardiology.
  • Immunosuppression, recurrent infection, prior malignancy → avoid inflammation-lowering biologics outside trials.
  • Pregnancy/breastfeeding.

Harm likely to outweigh benefit with current evidence:

  • Routine aspirin, canakinumab, senolytics, rapalogues, or IL-6 inhibitors given to healthy adults for “longevity” outside a trial — no efficacy evidence, real harms.

9. Practical management scenarios

Scenario A — Middle-aged adult, multiple cardiometabolic risk factors, hsCRP 3.5 mg/L.

  • Recommendation: Offer intensive lifestyle and dietary optimisation (Strong); Consider omega-3 for biomarker reduction (Conditional, surrogate endpoint). Do not start colchicine unless they meet the licensed high CV-risk/ASCVD criteria.
  • Assessment: confirm hsCRP on repeat, exclude occult cause, calculate QRISK3, optimise lipids/BP/glucose.
  • Shared decision-making: explain inflammation as a modifiable risk contributor; be explicit that biomarker lowering is not proven to extend lifespan.
  • Initiation: Mediterranean/DASH diet, ≥150 min/week exercise, smoking cessation, weight loss; consider statin intensification if hsCRP remains >2 mg/L irrespective of LDL (Mensah et al., 2026).
  • Monitoring: hsCRP + metabolic panel at 3 months, then 6–12 monthly.
  • Escalate/refer: persistent hsCRP >10 mg/L → investigate; if established ASCVD emerges → cardiology for licensed colchicine.

Scenario B — Older, frail patient with multimorbidity, elevated IL-6/hsCRP.

  • Recommendation: Offer tailored lifestyle measures (protein-adequate anti-inflammatory diet, resistance/aerobic exercise as tolerated) (Conditional). Avoid experimental pharmacotherapy and routine aspirin (ASPREE: no benefit, added harm).
  • Assessment: frailty and polypharmacy review, renal/hepatic function, exclude infection/malignancy.
  • Shared decision-making: prioritise function and avoidance of iatrogenesis; higher infection/toxicity susceptibility.
  • Initiation: graded exercise, nutrition, deprescribing where possible.
  • Monitoring: function and tolerability; conservative biomarker follow-up.
  • Escalate/refer: new organ-specific inflammation or unexplained persistent elevation → secondary care.

Scenario C — Patient with established ASCVD already under cardiology, residual hsCRP >2 mg/L on statin.

  • Recommendation: Consider/Offer low-dose colchicine 0.5 mg daily as an adjunct to lipid-lowering, coordinated with the cardiology team (Strong, within its licensed indication) (Mensah et al., 2026).
  • Assessment: confirm preserved renal/hepatic function; screen for interacting CYP3A4/P-gp inhibitors.
  • Shared decision-making: discuss ~25% MACE RRR from pooled data vs GI intolerance and infection signal.
  • Initiation: start 0.5 mg once daily; not at the time of acute ischaemia.
  • Monitoring: GI tolerance, FBC, renal/hepatic function; hold during interacting antibiotics/antifungals.
  • Escalate/refer: myopathy, cytopenia or serious infection → stop and reassess with cardiology.

10. Research gaps and future directions

  • No RCT demonstrates that lowering inflammation in healthy adults extends healthspan or lifespan; current longevity practice relies on surrogate biomarkers whose linkage to hard outcomes is proven only in cardiovascular secondary prevention.
  • Metformin for ageing: awaiting TAME and VA-IMPACT.
  • IL-6 ligand inhibition (ziltivekimab, clazakizumab): phase 3 outcomes expected late 2026–2027 (CKD, HFpEF, dialysis, ACS) (Mensah et al., 2026).
  • Senolytics and rapalogues: require adequately powered human efficacy trials on functional/ageing endpoints; presently early-phase and well-tolerated only.
  • Biomarker validation: whether methylation-based inflammation scores (EIS) or pace-of-ageing clocks (DunedinPACE) can serve as treatment-guiding endpoints is unproven (Verschoor et al., 2023; Humaloja et al., 2026).
  • Priority questions: optimal patient selection by inflammatory phenotype; whether biomarker lowering translates to clinical benefit in non-CVD populations; long-term safety of chronic anti-inflammatory therapy in the healthy.
  • Practice recommendation: experimental pharmacological anti-inflammatory/gerotherapeutic use for longevity should ideally occur within registries or well-designed clinical trials, not routine clinic prescribing.

Footnote

The strongest human anchor is that inflammation is causally linked to at least one age-related disease (CANTOS IL-1β blockade), and that lowering it reduces hard cardiovascular events (colchicine, ~25% MACE RRR in pooled data including the neutral CLEAR-SYNERGY) — but this is confined to cardiovascular secondary prevention, not general longevity.[4][7][6] For healthy or longevity populations, the evidence collapses to surrogate biomarker endpoints (hsCRP/IL-6 reductions with omega-3, ARBs, probiotics, metformin per the 2018 meta-analysis) with substantial heterogeneity, plus lifestyle interventions that have genuine hard-outcome support.[2][6] Metformin, senolytics and rapalogues remain research-only for the ageing indication, and daily aspirin is explicitly recommended against in healthy older adults (ASPREE).[4][5] The document flags each off-label, experimental and mechanism-only claim accordingly. A relevant caveat: hsCRP >10 mg/L should trigger a search for occult infection, malignancy or autoimmune disease rather than being attributed to inflammaging.

References

  1. Dietary Bioactive Compounds and Inflammaging: Pro-Inflammatory Triggers and Geroprotective Countermeasures. Moskalev A, Veselova O, Calabrese V, Rashan L, Franceschi C. Ageing Research Reviews. 2026;121:103241. doi:10.1016/j.arr.2026.103241.
  2. Evidence-Based Nutritional and Pharmacological Interventions Targeting Chronic Low-Grade Inflammation in Middle-Age and Older Adults: A Systematic Review and Meta-Analysis. Custodero C, Mankowski RT, Lee SA, et al. Ageing Research Reviews. 2018;46:42-59. doi:10.1016/j.arr.2018.05.004.
  3. Cellular Senescence, Inflammaging and Cardiovascular Disease. Zanders L, Arifaj D, Wagner JUG, Dimmeler S. Immunological Reviews. 2026;337(1):e70084. doi:10.1111/imr.70084.
  4. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
  5. Geroscience. Kritchevsky SB, Cummings SR. JAMA. 2025;334(12):1094-1102. doi:10.1001/jama.2025.11289.
  6. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Journal of the American College of Cardiology. 2026;87(11):1381-1404. doi:10.1016/j.jacc.2025.08.047.
  7. Targeting Inflammation After Acute Myocardial Infarction. Imbesi A, Greco A, Spagnolo M, et al. Journal of the American College of Cardiology. 2025;86(15):1146-1169. doi:10.1016/j.jacc.2025.07.064.